Published in Diabetes Care on June 14, 2010
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. PLoS One (2011) 1.31
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation (2016) 1.06
Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf (2013) 1.05
Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control (2012) 1.01
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr (2011) 0.94
Clinical benefits of metformin in gynecologic oncology. Oncol Lett (2015) 0.91
Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai. PLoS One (2013) 0.88
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia (2012) 0.88
Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One (2012) 0.87
The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem (2013) 0.86
Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care (2013) 0.85
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS One (2012) 0.85
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res (2015) 0.85
Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One (2014) 0.84
Insulin analogs and cancer. Front Endocrinol (Lausanne) (2012) 0.83
Role of insulin in the type 2 diabetes therapy: past, present and future. Int J Endocrinol Metab (2013) 0.83
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J Nutr Metab (2011) 0.83
Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes. BMC Cancer (2015) 0.82
Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol (2012) 0.82
Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study. PLoS One (2013) 0.81
Human insulin does not increase bladder cancer risk. PLoS One (2014) 0.80
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes (2012) 0.80
Cancer biology in diabetes. J Diabetes Investig (2014) 0.79
Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma. BMC Res Notes (2013) 0.79
Insulin concerns and promises. Diabetes Care (2011) 0.78
Impaired glucose metabolism treatment and carcinogenesis. Oncol Lett (2015) 0.77
Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. PLoS One (2014) 0.77
Insulin therapy. Wien Med Wochenschr (2011) 0.75
Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia (2009) 7.06
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia (2009) 3.89
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia (2009) 3.82
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 3.74
Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev (2009) 3.37
Insulin glargine and malignancy: an unwarranted alarm. Lancet (2009) 3.19
1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens (1999) 2.72
Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia (2009) 2.34
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care (2005) 1.82
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer (2006) 1.47
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia (2009) 1.38
Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res (2008) 1.30
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2008) 1.30
Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care (2008) 1.26
Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem (2010) 1.12
ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog (1997) 1.02
Long-acting insulin analogs. Diabetes Care (1999) 0.96
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev (2007) 0.94
Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine. Diabetologia (2009) 0.84
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Low diastolic ambulatory blood pressure is associated with greater all-cause mortality in older patients with hypertension. J Am Geriatr Soc (2009) 2.28
Prognostic stratification of older persons based on simple administrative data: development and validation of the "Silver Code," to be used in emergency department triage. J Gerontol A Biol Sci Med Sci (2009) 1.85
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol (2011) 1.60
DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther (2011) 1.59
Sulphonylureas and cancer: a case-control study. Acta Diabetol (2008) 1.56
Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med (2010) 1.54
Cardiovascular health in migrants: current status and issues for prevention. A collaborative multidisciplinary task force report. J Cardiovasc Med (Hagerstown) (2014) 1.50
Management of acute myocardial infarction in the real world: a summary report from The Ami-Florence Italian Registry. Intern Emerg Med (2008) 1.48
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev (2006) 1.47
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism (2008) 1.43
Prognostic impact of atrial fibrillation occurrence in patients with non-ST-elevation acute coronary syndromes: is dysrhythmia duration a parameter to focus on? Intern Emerg Med (2013) 1.38
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care (2008) 1.33
The diabetic cardiomyopathy. Acta Diabetol (2010) 1.32
Lower extremity performance measures predict long-term prognosis in older patients hospitalized for heart failure. J Card Fail (2010) 1.32
Risk factors for disability in older persons over 3-year follow-up. Age Ageing (2009) 1.29
Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol (2009) 1.25
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract (2007) 1.23
Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care (2010) 1.22
Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. Diabetes Care (2009) 1.19
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation (2013) 1.13
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res (2011) 1.12
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care (2007) 1.12
Metformin beyond diabetes: new life for an old drug. Curr Diabetes Rev (2006) 1.11
Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab (2002) 1.11
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol (2013) 1.10
The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail (2009) 1.08
Diagnostic crossover and outcome predictors in eating disorders according to DSM-IV and DSM-V proposed criteria: a 6-year follow-up study. Psychosom Med (2011) 1.08
Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev (2011) 1.05
On the relationship between smoking bans and incidence of acute myocardial infarction. Eur J Epidemiol (2009) 1.04
Nine-year follow-up of a survey on smoking habits in Florence (Italy): higher mortality among non-responders. Int J Epidemiol (2002) 1.02
Is glucose control important for prevention of cardiovascular disease in diabetes? Diabetes Care (2013) 1.01
TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res (2011) 1.00
Hospital discharge data for assessing myocardial infarction events and trends, and effects of diagnosis validation according to MONICA and AHA criteria. J Epidemiol Community Health (2010) 1.00
Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. J Biol Chem (2003) 0.99
Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med (2009) 0.99
Cystatin C reference values and aging. Clin Biochem (2006) 0.99
Correlations between binge eating and emotional eating in a sample of overweight subjects. Appetite (2009) 0.99
Finger sepsis in two poorly controlled diabetic patients with reuse of lancets. Diabetes Care (2002) 0.99
Serum PSA as a predictor of testosterone deficiency. J Sex Med (2013) 0.96
Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clin Exp Res (2007) 0.96
Short-term association between ambient air pollution and risk of hospitalization for acute myocardial infarction: results of the cardiovascular risk and air pollution in Tuscany (RISCAT) study. Am J Epidemiol (2011) 0.96
Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res (2005) 0.95
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol (2009) 0.95
Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis (2007) 0.93
Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetol (2011) 0.93
Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med (2010) 0.93
Prognostic stratification of elderly patients in the emergency department: a comparison between the "Identification of Seniors at Risk" and the "Silver Code". J Gerontol A Biol Sci Med Sci (2011) 0.92
Aggressiveness, anger and eating disorders: a review. Psychopathology (2006) 0.92
Oxidative DNA damage in peripheral blood cells in type 2 diabetes mellitus: higher vulnerability of polymorphonuclear leukocytes. Mutat Res (2003) 0.91
Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetol (2012) 0.91
Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res (2004) 0.91
Comparison of individual and group cognitive behavioral therapy for binge eating disorder. A randomized, three-year follow-up study. Appetite (2010) 0.90
Skin autofluorescence in type 2 diabetes: beyond blood glucose. Diabetes Res Clin Pract (2007) 0.90
Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetol (2010) 0.88
Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther (2012) 0.88
[Objectives, tools and methods for an epidemiological use of electronic health archives in various areas of Italy]. Epidemiol Prev (2008) 0.88
Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS). BMC Med Res Methodol (2013) 0.87
Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study. Diabetes Metab Res Rev (2006) 0.87
Rheumatological manifestations in diabetes mellitus. Curr Diabetes Rev (2006) 0.87
Predictors of recovery of ovarian function after weight gain in subjects with amenorrhea related to restrictive eating disorders. Gynecol Endocrinol (2008) 0.87
Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. Int J Cardiol (2006) 0.86
Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy. Cancer Causes Control (2002) 0.86
Body composition variables and leptin levels in functional hypothalamic amenorrhea and amenorrhea related to eating disorders. J Pediatr Adolesc Gynecol (2011) 0.86
Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutat Res (2007) 0.86
Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. Am Heart J (2006) 0.86
Bone: incretin hormones perceiver or receiver? Exp Diabetes Res (2012) 0.86
Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med (2010) 0.86
Ozone short-term exposure and acute coronary events: a multicities study in Tuscany (Italy). Environ Res (2013) 0.86
Is obesity a further cardiovascular risk factor in patients with erectile dysfunction? J Sex Med (2010) 0.85
In-hospital management and outcome in women with acute myocardial infarction (data from the AMI-Florence Registry). Am J Cardiol (2004) 0.85
Rosiglitazone and cardiovascular risk. N Engl J Med (2007) 0.85
Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance. Acta Diabetol (2011) 0.85